We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Cardiac Researchers Use Stem Cells to Generate Functional Heart Muscle

By LabMedica International staff writers
Posted on 03 May 2016
Stem cell researchers have developed a new technique to form micro-scale arrays of engineered heart muscle (EHM) from fewer than 10,000 starter cells without requirement for adherence features or extracellular matrix (ECM).

Tissue engineering approaches have the potential to increase the physiologic relevance of cells, such as cardiomyocytes, derived from human induced pluripotent stem cells (iPSCs). More...
However, forming engineered heart muscle (EHM) typically requires more than one million cells per tissue. Existing miniaturization strategies involve complex approaches not suitable for mass production, limiting the ability to use EHM for iPSC-based disease modeling and drug screening. Microscale cardiospheres are easily produced, but do not facilitate assembly of elongated muscle or direct force measurements.

Investigators at the Gladstone Institute (San Francisco, CA, USA) recently described a new approach for preparing EHM that dramatically reduced the number of cells needed, making it an easier, cheaper, and more efficient system.

Initially, the investigators generated heart muscle cells and connective tissue cells from iPSCs. They then cultured combinations of these cells in a special vessel that resembled a tiny dog bone. This unique shape encouraged the cells to self-organize into elongated muscle fibers. Within a few days, the micro tissues resembled heart muscle both structurally and functionally.

The EHM prepared by this method exhibited uniaxial contractility and alignment, robust sarcomere assembly, and reduced variability and hypersensitivity in drug responsiveness compared to monolayers with the same cellular composition.

“The beauty of this technique is that it is very easy and robust, but it still allows you to create three-dimensional miniature tissues that function like normal tissues,” said senior author Dr. Bruce Conklin, senior investigator of cardiovascular disease at the Gladstone Institute. “Our research shows that you can create these complex tissues with a simple template that exploits the inherent properties of these cells to self-organize. We think that the micro heart muscle will provide a superior resource for conducting research and developing therapies for heart disease.”

Related Links:
Gladstone Institute


New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Pipette Calibration System
Artel PCS®
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.